Weight Loss
Weight-loss that remits type 2 diabetes normalizes beta-cell function
Adults with type 2 diabetes who lose enough weight to enter diabetes remission are also able to recapture normal beta-cell capacity, according to findings published in Diabetes Care.
FDA requests withdrawal of weight-loss drug due to cancer risk
The FDA requested that the manufacturer of the serotonin receptor agonist lorcaserin voluntarily withdraw the weight-loss drug from the U.S. market because of clinical trial data that show an increased occurrence of cancer, according to an agency alert issued today.
Additional physical activity in school can yield cost-effective weight benefits for children
The Daily Mile, a school-based physical activity program in addition to physical education, may be considered a favorable and cost-effective approach to childhood obesity prevention when compared to the usual health and wellbeing activities in schools, according to findings from a recent study.
Top stories in endocrinology: FDA OKs first triple combination pill for diabetes, apps help people with diabetes lose weight
The FDA approved Trijardy XR, the first oral therapy to combine three type 2 diabetes medications into one pill. It was the week’s top story in endocrinology.
Shared medical appointments for obesity management associated with greater weight loss vs. usual care
Shared medical appointments may offer a favorable strategy for obesity management with greater weight loss and more access to antiobesity medications compared with individual medical visits alone, according to findings from a recent study.
Mobile apps may facilitate weight loss among adults with type 2 diabetes
Adults with type 2 diabetes may lose weight more effectively by including a weight-loss mobile app as part of their strategy, according to findings from a meta-analysis published in Obesity.
Sustained weight loss lowers risk for breast cancer
Women aged 50 years and older who had sustained weight loss over more than 8 years demonstrated a decreased risk for breast cancer compared with women whose weight remained stable, according to results of a pooled analysis published in Journal of the National Cancer Institute.
In obesity, growing CV risk burden demands cross-specialty collaboration, new solutions
The prevalence of obesity in the U.S. is rising at an alarming rate, as are its CV consequences, a result of greater consumption of high-calorie foods, decreases in regular physical activity and increases in psychosocial stresses, especially in disadvantaged populations. In an analysis of 10 large prospective cohorts with long-term follow-up published recently in JAMA Cardiology, researchers found that adults with obesity had significantly increased lifetime risk for CV morbidity and mortality and typically had a shorter life span compared with those with a normal BMI. In addition, elevated BMI conferred the greatest risk for incident HF among CVD subtypes.
Despite similar weight loss, low-carbohydrate diet delivers insulin reductions, smaller fat cells than low-fat diet
LOS ANGELES — Eating plans low in carbohydrates result in smaller fat cells vs. low-fat/higher-carbohydrate plans after similar weight loss, which may yield better metabolic health, according to a speaker at the World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease.
Semaglutide injection bests canagliflozin, liraglutide in head-to-head type 2 diabetes trials
Favorable results from separate SUSTAIN trials pitting the GLP-1 receptor agonist semaglutide against the SGLT2 inhibitor canagliflozin and against the popular GLP-1 receptor agonist liraglutide were presented and simultaneously published in journals.